Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

    AGBA

    MCap

    USD211m

    Last close

    USD2.83

    ▲ 0.48 (20.43%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

SIGA Technologies (NASDAQ: SIGA)

Last close As at 30/04/2024

USD8.78

▲ −0.05 (−0.57%)

Market capitalisation

USD625m

SIGA Technologies is a commercial-stage health security company focused on the treatment of smallpox and other orthopoxvirus. It has contracts with both the US and Canadian governments for TPOXX, its treatment for smallpox, and is expanding internationally.

With c 94,000 global cases and 32,000 cases in the US since 2022, mpox remains a growing concern especially given the rising numbers of clade 1 (severe) cases in Democratic Republic of Congo. TPOXX was approved by the US FDA for smallpox and is now available to treat mpox through the Centers for Disease Control and Prevention’s expanded access investigational new drug protocol. Currently, it is the only allowed therapy for all orthopoxvirus pathogens, including mpox, approved in both the UK and the EU.

Latest Insights

View More

Healthcare | Flash note

SIGA Technologies — Positive signals abound

Healthcare | Update

SIGA Technologies — Onwards and upwards with strong FY23

Healthcare | Flash note

SIGA Technologies — New captain to steer the ship

Healthcare | Update

SIGA Technologies — International momentum building towards year-end
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Daniel Luckshire

    Executive VP and CFO

  • Diem Nguyen

    CEO

Balance Sheet

Forecast net cash (US$m)

166.6

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 2.6 79.9 50.6
Relative 7.0 73.1 24.7
52 week high/low US$9.9/US$4.3

Financials

SIGA Technologies is a commercial-stage company focused on the treatment of smallpox and other orthopoxviruses. Lead drug TPOXX was approved by the US FDA in 2018 for the treatment of smallpox and in the EU and UK under the broad label including all orthopox pathogens in 2022. SIGA reported solid FY23 results, with product revenues growing 50.8% to $130.7m driven by Q423 deliveries to the US SNS and HERA, and management announcing a special cash dividend of $0.6/share. Following an amended contract with Meridian, SIGA will actively manage international promotion activities effective June 2024. We continue to view the PEP label expansion as a key future value driver for SIGA and view the commercial launch of Jynneos vaccine (SIGA peer) as a positive for the company.

Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (fd) (c) P/E (x) P/CF (x)
2022A 110.8 43.2 43.7 45.56 19.3 15.4
2023A 139.9 84.2 87.8 94.96 9.2 6.6
2024E 190.6 104.4 108.4 122.41 7.2 10.5
2025E 169.3 96.3 100.7 118.95 7.4 8.3

Update

Healthcare

SIGA Technologies — Solid results marked by revenue diversification

Update

Healthcare

SIGA Technologies — Solid Q322, underpinned by international traction

Flash note

SIGA Technologies — TPOXX trials launched in treating monkeypox

edison tv

Healthcare

SIGA Technologies – executive interview

Flash note

Healthcare

SIGA Technologies — Second contract win from the US DoD in 2022

Flash note

Healthcare

SIGA Technologies — Monkeypox concern drives international TPOXX win

Update

Healthcare

SIGA Technologies — Monkeypox likely here to stay

Flash note

Healthcare

SIGA Technologies — BARDA exercises first option for IV TPOXX

Flash note

Healthcare

SIGA Technologies — Best is yet to come

Flash note

Healthcare

SIGA Technologies — WHO declares monkeypox a global emergency

Flash note

Healthcare

SIGA Technologies — The year of international expansion

Flash note

Healthcare

SIGA Technologies — International expansion for oral TPOXX

Flash note

Healthcare

SIGA Technologies — IV TPOXX receives FDA Approval

Update

Healthcare

SIGA Technologies — Product and international expansion on track

Update

Healthcare

SIGA Technologies — Geographic expansion underway

Update

Healthcare

SIGA Technologies — Additional approvals expected shortly

edison tv

Healthcare

SIGA Technologies – executive interview

Update

Healthcare

SIGA Technologies — Q221 results

edison tv

Healthcare

SIGA Technologies and Cipla Therapeutics – executive interview

Update

Healthcare

SIGA Technologies — Additional international deal possible in Q2

edison tv

Healthcare

SIGA Technologies – executive interview

Initiation

Healthcare

SIGA Technologies — Protection against a future pandemic